Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of DNA-PK (unknown origin)
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
SummaryRelated BioAssays by Target
DNAPK Enzyme Potency Assay (DNA-PK Enz) from US Patent US11884671: "Purinone compounds and their use in treating cancer"
Assay data:51 Active, 43 Activity ≤ 1 nM, 51 Activity ≤ 1 µM, 51 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Assay of ATR Kinase Activity from US Patent US20230271968: "PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR"
Assay data:24 Active, 24 Activity ≤ 1 µM, 24 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Z′-LYTE Biochemical Aassay from US Patent US11673876: "Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors"
Assay data:16 Active, 16 Activity ≤ 1 µM, 16 Tested
PI3K-Alpha kinase (PIK3CA) activity, wild-type and H1047R mutant and determining IC50 values for inhibitors from US Patent US11649227: "Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease"
Assay data:92 Active, 74 Activity ≤ 1 µM, 98 Tested
Inhibition of DNA-PK (unknown origin) assessed as residual activity at 1 uM relative to control
Assay data:2 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of DNA-PK (unknown origin) at 50 nM by Z'LYTE screening method relative to control
Assay data:12 Tested
Inhibition of DNA-PK (unknown origin) using EPPLSQEAFADLWKK peptide as substrate preincubated with compound for 30 mins followed by substrate addition and further incubated for 40 mins in presence of ATP by TR-FRET assay
Assay data:19 Active, 11 Activity ≤ 1 nM, 19 Activity ≤ 1 µM, 19 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of DNA-PK in human A549 cells assessed as reduction in irradiation-induced autophosphorylation at S2056 residue preincubated for 1 hr followed by 8 Gy irradiation and measured after 1 hr by ELISA
Assay data:19 Active, 16 Activity ≤ 1 µM, 19 Tested
Inhibition of DNA-PK (unknown origin) assessed as inhibition constant using Glu-Pro-Pro-Leu-Ser-Gln-Glu-Ala-Phe-Ala-Asp-Leu-Trp-Lys-Lys-Lys peptide as substrate incubated for 45 mins in presence of [33P]-ATP by scintillation counting method
Inhibition of full-length human DNA-PK expressed in baculovirus expression system using p53 as substrate incubated for 1 hr in presence of ATP by ELISA
Assay data:2 Active, 2 Activity ≤ 1 nM, 2 Activity ≤ 1 µM, 2 Tested
Assay data:3 Active, 1 Activity ≤ 1 nM, 3 Activity ≤ 1 µM, 3 Tested
Inhibition of DNA-PK (unknown origin) incubated for 3 hrs by ADP-Glo kinase assay
Assay data:3 Active, 3 Activity ≤ 1 µM, 3 Tested
Inhibition of human DNA-PK using p53 as substrate incubated for 30 mins in presence of by HTRF assay
Assay data:4 Active, 2 Activity ≤ 1 nM, 4 Activity ≤ 1 µM, 4 Tested
Inhibition of DNA-PK in bleomycin-treated human HCT-116 cells assessed as reduction in gammaH2AX expression at 20 uM pretreated with compound followed by bleomycin addition and measured after 6 hrs by western blot analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of DNA-PK in bleomycin-treated human HCT-116 cells assessed as reduction in gammaH2AX expression pretreated with compound followed by bleomycin addition and measured after 6 hrs by western blot analysis
Assay data:1 Tested
Inhibition of DNA-PK in bleomycin-treated human HCT-116 cells assessed as reduction in gammaH2AX expression at 20 uM pretreated with compound followed by bleomycin addition and measured after 6 hrs by DAPI staining based immunofluorescence analysis
Inhibition of DNA-PK in bleomycin-treated human HCT-116 cells assessed as reduction in gammaH2AX expression pretreated with compound followed by bleomycin addition and measured after 6 hrs by DAPI staining based immunofluorescence analysis
Inhibition of human native full length DNA-PK by ADP-Glo assay
Assay data:15 Active, 1 Activity ≤ 1 nM, 15 Activity ≤ 1 µM, 15 Tested
Inhibition of DNA-PK (unknown origin) in the presence of ATP
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on